For research use only. Not for use in humans.

Dostarlimab (Anti-PDCD1 / PD-1 / CD279)

Synonyms: null

Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.

Dostarlimab (Anti-PDCD1 / PD-1 / CD279)

Quality Control

Batch: A283501 Purity: 99% Protein concentration: 4.22mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 13
BMS-1 13
BMS202 26
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 3
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.
References

Product Details

CAS No. 2022215-59-2
Molecular Weight 144.18
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.